The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Incretin-Based Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The global Incretin-Based Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Incretin-Based Drugs in various end use industries. The expanding demands from the Oral Drugs and Injectable Drugs, are propelling Incretin-Based Drugs market. Glucagon-like peptide-1 receptor (GLP-1) agonists, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dipeptidyl Peptidase-4 (DPP-4) inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Incretin-Based Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Incretin-Based Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Incretin-Based Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Incretin-Based Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Incretin-Based Drugs covered in this report include GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company and Sanofi, etc.
The global Incretin-Based Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Global Incretin-Based Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Incretin-Based Drugs market, Segment by Type:
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Global Incretin-Based Drugs market, by Application
Oral Drugs
Injectable Drugs
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Incretin-Based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Incretin-Based Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Incretin-Based Drugs in various end use industries. The expanding demands from the Oral Drugs and Injectable Drugs, are propelling Incretin-Based Drugs market. Glucagon-like peptide-1 receptor (GLP-1) agonists, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Dipeptidyl Peptidase-4 (DPP-4) inhibitors segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Incretin-Based Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Incretin-Based Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Incretin-Based Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Incretin-Based Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Incretin-Based Drugs covered in this report include GlaxoSmithKline, Johnson & Johnson, Merck & Co, AstraZeneca, Novartis, Eli Lilly and Company, Boehringer Ingelheim, Takeda Pharmaceutical Company and Sanofi, etc.
The global Incretin-Based Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Johnson & Johnson
Merck & Co
AstraZeneca
Novartis
Eli Lilly and Company
Boehringer Ingelheim
Takeda Pharmaceutical Company
Sanofi
Global Incretin-Based Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Incretin-Based Drugs market, Segment by Type:
Glucagon-like peptide-1 receptor (GLP-1) agonists
Dipeptidyl Peptidase-4 (DPP-4) inhibitors
Global Incretin-Based Drugs market, by Application
Oral Drugs
Injectable Drugs
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Incretin-Based Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Incretin-Based Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Incretin-Based Drugs Market Overview
1.1 Incretin-Based Drugs Product Overview
1.2 Incretin-Based Drugs Market Segment by Type
1.2.1 Glucagon-like peptide-1 receptor (GLP-1) agonists
1.2.2 Dipeptidyl Peptidase-4 (DPP-4) inhibitors
1.3 Global Incretin-Based Drugs Market Size by Type
1.3.1 Global Incretin-Based Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global Incretin-Based Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global Incretin-Based Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Incretin-Based Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe Incretin-Based Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Incretin-Based Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Incretin-Based Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Incretin-Based Drugs Sales Breakdown by Type (2018-2023)
2 Global Incretin-Based Drugs Market Competition by Company
2.1 Global Top Players by Incretin-Based Drugs Sales (2018-2023)
2.2 Global Top Players by Incretin-Based Drugs Revenue (2018-2023)
2.3 Global Top Players by Incretin-Based Drugs Price (2018-2023)
2.4 Global Top Manufacturers Incretin-Based Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 Incretin-Based Drugs Market Competitive Situation and Trends
2.5.1 Incretin-Based Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Incretin-Based Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Incretin-Based Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into Incretin-Based Drugs Market
2.8 Key Manufacturers Incretin-Based Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Incretin-Based Drugs Status and Outlook by Region
3.1 Global Incretin-Based Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Incretin-Based Drugs Historic Market Size by Region
3.2.1 Global Incretin-Based Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global Incretin-Based Drugs Sales in Value by Region (2018-2023)
3.2.3 Global Incretin-Based Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Incretin-Based Drugs Forecasted Market Size by Region
3.3.1 Global Incretin-Based Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global Incretin-Based Drugs Sales in Value by Region (2024-2029)
3.3.3 Global Incretin-Based Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Incretin-Based Drugs by Application
4.1 Incretin-Based Drugs Market Segment by Application
4.1.1 Oral Drugs
4.1.2 Injectable Drugs
4.2 Global Incretin-Based Drugs Market Size by Application
4.2.1 Global Incretin-Based Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global Incretin-Based Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global Incretin-Based Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Incretin-Based Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe Incretin-Based Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Incretin-Based Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Incretin-Based Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Incretin-Based Drugs Sales Breakdown by Application (2018-2023)
5 North America Incretin-Based Drugs by Country
5.1 North America Incretin-Based Drugs Historic Market Size by Country
5.1.1 North America Incretin-Based Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Incretin-Based Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America Incretin-Based Drugs Sales in Value by Country (2018-2023)
5.2 North America Incretin-Based Drugs Forecasted Market Size by Country
5.2.1 North America Incretin-Based Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America Incretin-Based Drugs Sales in Value by Country (2024-2029)
6 Europe Incretin-Based Drugs by Country
6.1 Europe Incretin-Based Drugs Historic Market Size by Country
6.1.1 Europe Incretin-Based Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Incretin-Based Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe Incretin-Based Drugs Sales in Value by Country (2018-2023)
6.2 Europe Incretin-Based Drugs Forecasted Market Size by Country
6.2.1 Europe Incretin-Based Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe Incretin-Based Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific Incretin-Based Drugs by Region
7.1 Asia-Pacific Incretin-Based Drugs Historic Market Size by Region
7.1.1 Asia-Pacific Incretin-Based Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Incretin-Based Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Incretin-Based Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Incretin-Based Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific Incretin-Based Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Incretin-Based Drugs Sales in Value by Region (2024-2029)
8 Latin America Incretin-Based Drugs by Country
8.1 Latin America Incretin-Based Drugs Historic Market Size by Country
8.1.1 Latin America Incretin-Based Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Incretin-Based Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America Incretin-Based Drugs Sales in Value by Country (2018-2023)
8.2 Latin America Incretin-Based Drugs Forecasted Market Size by Country
8.2.1 Latin America Incretin-Based Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America Incretin-Based Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa Incretin-Based Drugs by Country
9.1 Middle East and Africa Incretin-Based Drugs Historic Market Size by Country
9.1.1 Middle East and Africa Incretin-Based Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Incretin-Based Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Incretin-Based Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Incretin-Based Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa Incretin-Based Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Incretin-Based Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Information
10.1.2 GlaxoSmithKline Introduction and Business Overview
10.1.3 GlaxoSmithKline Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GlaxoSmithKline Incretin-Based Drugs Products Offered
10.1.5 GlaxoSmithKline Recent Development
10.2 Johnson & Johnson
10.2.1 Johnson & Johnson Company Information
10.2.2 Johnson & Johnson Introduction and Business Overview
10.2.3 Johnson & Johnson Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Johnson & Johnson Incretin-Based Drugs Products Offered
10.2.5 Johnson & Johnson Recent Development
10.3 Merck & Co
10.3.1 Merck & Co Company Information
10.3.2 Merck & Co Introduction and Business Overview
10.3.3 Merck & Co Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Merck & Co Incretin-Based Drugs Products Offered
10.3.5 Merck & Co Recent Development
10.4 AstraZeneca
10.4.1 AstraZeneca Company Information
10.4.2 AstraZeneca Introduction and Business Overview
10.4.3 AstraZeneca Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 AstraZeneca Incretin-Based Drugs Products Offered
10.4.5 AstraZeneca Recent Development
10.5 Novartis
10.5.1 Novartis Company Information
10.5.2 Novartis Introduction and Business Overview
10.5.3 Novartis Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Novartis Incretin-Based Drugs Products Offered
10.5.5 Novartis Recent Development
10.6 Eli Lilly and Company
10.6.1 Eli Lilly and Company Company Information
10.6.2 Eli Lilly and Company Introduction and Business Overview
10.6.3 Eli Lilly and Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Eli Lilly and Company Incretin-Based Drugs Products Offered
10.6.5 Eli Lilly and Company Recent Development
10.7 Boehringer Ingelheim
10.7.1 Boehringer Ingelheim Company Information
10.7.2 Boehringer Ingelheim Introduction and Business Overview
10.7.3 Boehringer Ingelheim Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Boehringer Ingelheim Incretin-Based Drugs Products Offered
10.7.5 Boehringer Ingelheim Recent Development
10.8 Takeda Pharmaceutical Company
10.8.1 Takeda Pharmaceutical Company Company Information
10.8.2 Takeda Pharmaceutical Company Introduction and Business Overview
10.8.3 Takeda Pharmaceutical Company Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Takeda Pharmaceutical Company Incretin-Based Drugs Products Offered
10.8.5 Takeda Pharmaceutical Company Recent Development
10.9 Sanofi
10.9.1 Sanofi Company Information
10.9.2 Sanofi Introduction and Business Overview
10.9.3 Sanofi Incretin-Based Drugs Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Sanofi Incretin-Based Drugs Products Offered
10.9.5 Sanofi Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Incretin-Based Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Incretin-Based Drugs Industrial Chain Analysis
11.4 Incretin-Based Drugs Market Dynamics
11.4.1 Incretin-Based Drugs Industry Trends
11.4.2 Incretin-Based Drugs Market Drivers
11.4.3 Incretin-Based Drugs Market Challenges
11.4.4 Incretin-Based Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Incretin-Based Drugs Distributors
12.3 Incretin-Based Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
